We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Biomarker Determined for Colorectal Cancer

By LabMedica International staff writers
Posted on 02 Jul 2013
A highly sensitive blood test can detect cancer related micro-ribonucleic acid (miRNA) before any signs of the disease manifests. More...


Increased expression of circulating miRNAs could be indicative of miRNAs secreted from a tumor, raising the overall diagnostic specificity of biomarkers, especially if they can be measured in blood or serum samples.

Scientists at the Baylor Research Institute (Dallas, TX, USA) analyzed 568 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas and cancers at the Mie University Medical Hospital (Tsu, Japan), between January 1, 2005 and December 31, 2010.

MiRNA extraction from serum and culture media samples was performed with miRNeasy RNA isolation Kits (Qiagen; Valencia, CA, USA), whereas miRNA extraction from formalin-fixed and paraffin-embedded (FFPE) samples was performed using RecoverAll Total Nucleic Acid Isolation Kits (Ambion Inc.; Austin, TX, USA). The TaqMan miRNA quantitative reverse-transcription polymerase chain reaction (qRT-PCR; Applied Biosystems; Foster City, CA, USA) were used to detect and quantify miRNA expression.

By measuring levels of miR-21 in the blood, the scientists could accurately identify up to 92% of patients with colorectal cancer. Even more importantly, not only is this test good for noninvasively identifying patients who already have colorectal cancer, but it can accurately identify up to 82% of patients with advanced colonic polyps, which present the highest risk for developing into colorectal cancers several years later in life.

Ajay Goel, PhD, the lead investigator said, “The development of this biomarker is highly encouraging because high mortality rates associated with colorectal cancer is a consequence of late detection of this disease, underscoring the need for improved early detection, prevention, risk assessment, and intervention. Michael Ramsay, MD, the president of Baylor Research Institute, added, “This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars.” The study was published on May 23, 2013, in the Journal of the National Cancer Institute.

Related Links:

Baylor Research Institute
Mie University Medical Hospital
Qiagen



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.